Aspen Neuroscience
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | dopaminergic neuron replacementCell therapy | Parkinson's Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
19 March 2026PresentationSasineprocelASPIRO Phase 1/2a (NCT06344026) 12-month data at AD/PD 2026: open-label, n=8, engraftment with motor and quality-of-life signals
Financial reports
No financial reports recorded.